Copyright ©The Author(s) 2021.
World J Gastrointest Surg. Aug 27, 2021; 13(8): 796-805
Published online Aug 27, 2021. doi: 10.4240/wjgs.v13.i8.796
Table 1 Retrospective study published concentrating on surgical treatment for hepatocellular carcinoma patients with tumor thrombus in hepatic vein
Location of tumor thrombus
Patient number
Prognostic factors
Chen et al[7], 2020Surgery, TACE, supportive treatmentHV, IVC43727.1 mo for type 1; 15 mo for type 2; 8 mo for type 3HVTT classification, treatment modality, coexistence of PVTT, total bilirubin, tumor diameter
Kokudo et al[4], 2017Surgical vs no surgicalHV, IVC651 vs 6154.47 yr vs 1.58 yr in pHVTT/mHVTT; 1.48 yr vs 0.84 yr in IVCTTIn pHVTT/mHVTT, PVTT, number of tumors, gastroesophageal varcices, poor cell differentiation
Li et al[14], 2015Hepatectomy en bloc vs hepatectomy combined with suction of tumor thrombusHV or portal vein28 vs 2814.3 mo vs 10.4 moPreoperative AFP level, treatment choice
Kokudo et al[6], 2014Hepatectomy combined with or without thrombectomyHV, IVC1745.27 yr for pHVTT; 3.95 yr for mHVTT; 1.39 yr for IVCTTLocation of tumor thrombus, R1/2 resection
Wang et al[12], 2013Hepatectomy and tumor thrombectomy vs TACE vs symptomatic treatmentIVC or RA 25 vs 20 vs 1119 mo vs 4 mo vs 5 moNumber of tumor nodules, treatment choice
Liu et al[5], 2012Hepatectomy and tumor thrombectomy vs TACE + chemotherapyRHV or IVC65 vs 5018 mo vs 7 moNot mentioned